Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • boilermaker
    Junior Member
    • Apr 2014
    • 5

    #1

    Mapping to Genome vs Transcriptome?

    Dear SEQanswers community:

    I hope this is not a duplicate of earlier threads, but I was wondering the following:

    We have been using the Tophat2 -> htSeq -> edgeR/DESeq2 pipeline for differential expression analysis of human RNA-seq data for several years. We typically align our fastq files to a human genome build, then use a suitable GTF file to assign feature counts prior to differential expression analysis.

    A colleague recently suggested that it might be better to map to an annotated human transcriptome, rather than a genome build, in this pipeline.

    I was led to believe that mapping to the genome was generally preferred for differential expression analysis. I also thought that assignment of feature counts using an annotated GTF file, in effect, focused the reads around the transcriptome.

    I have seen many papers examining the relative merits/problems with mapping to the variously annotated transcriptome resources (e.g., ACEVIEW, Ensembl, RefSeq, etc.), but I have not yet come across any papers in which these were compared to genome matching and feature counting using htSeq.

    I was wondering if I might be missing some key resources? As well, I was wondering if members of the community had any opinions on this issue, based on their experiences. Has anyone tried such a comparison?

    Thanks in advance for any advice you might be able to provide.
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    Consider these past informative threads:

    Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc

    Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc

    Comment

    • boilermaker
      Junior Member
      • Apr 2014
      • 5

      #3
      Thank you. I had not come across these threads previously, but am happy to see that others have grappled with this issue.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-22-2026, 11:13 AM
      0 responses
      27 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 10:48 AM
      0 responses
      20 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      36 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      43 views
      0 reactions
      Last Post SEQadmin2  
      Working...